Results 31 to 40 of about 4,315,874 (223)
Objective: The aim of this work was to demonstrate a possible relationship between anti-latency-associated peptide human latent transforming growth factor beta 1 (latent TGF-β1) expression in megakaryocytes and microvascular density in bone marrow ...
Cesar Cilento Ponce +3 more
doaj +1 more source
In primary myelofibrosis, extra-domain A fibronectin (EDA-FN), the result of alternative splicing of FN gene, sustains megakaryocyte proliferation and confers a pro-inflammatory phenotype to bone marrow cell niches. In this work we assessed the levels of
Alessandro Malara +6 more
doaj +1 more source
PREFERENTIAL NUCLEAR ACCUMULATION OF JAK2V617F IN CD34+ BUT NOT IN GRANULOCYTIC, MEGAKARYOCYTIC OR ERYTHROID CELLS OF PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA. [PDF]
Recently, Dawson et al. identified a previously unrecognized nuclear role for JAK2 in the phosphorylation of the tyrosine 41 of the histone H3 with the exclusion of HP1a from chromatin and resulting in a disregulation of several JAK2-regulated genes such
Rinaldi, Ciro Roberto
core +2 more sources
Targeted sequencing of candidate gene regions for myelofibrosis in dogs
Background Myelofibrosis often lacks an identifiable cause in dogs. In humans, most primary myelofibrosis cases develop secondary to driver mutations in JAK2, CALR, or MPL.
Amelia G. Campbell +7 more
doaj +1 more source
Primary Hypertrophic Osteoarthropathy With Myelofibrosis
Primary hypertrophic osteoarthropathy (PHO) is a rare autosomal recessive inherited multi-system disorder characterized by a triad of pachydermia, periostosis, and clubbing. PHO was revealed to be caused by the HPGD gene producing 15-prostaglandin dehydrogenase and the SLCO2A1 gene expressing one kind of prostaglandin transporter.
Yousaf, Muhammad +4 more
openaire +2 more sources
Risk stratification in primary myelofibrosis is currently based on two international prognostic scoring systems, neither of which takes into consideration red blood cell transfusion-dependency.
Chiara Elena +9 more
doaj +1 more source
Thalidomide treatment in a myelofibrosis patient with leukemia transformation
Primary myelofibrosis is a clonal disease of chronic myeloproliferative neoplasm, and is a progressive clinical course with short median survival of less than 5 years after diagnosis.
Huang, Wei-Han;Li, Ming-Shing;Chu, Sung-Chao;Wang, Tso-Fu;Kao, Ruey-Ho;Wu, Yi-Feng
core +1 more source
Refractory gout in primary myelofibrosis [PDF]
![Figure][1] A 66-year-old man from the Dominican Republic presented to the Myeloproliferative Neoplasms Clinic at Mount Sinai with a 10-year history of untreated JAK2V617F- positive primary myelofibrosis (PMF).
Sangeetha Venugopal, John Mascarenhas
openaire +2 more sources
Urticarial vasculitis coexisting with primary myelofibrosis – a case report
Introduction . Urticarial vasculitis is a subtype of cutaneous leukocytoclastic vasculitis. The disease often accompanies systemic disorders, including hematologic malignancies, connective tissue diseases, and infectious diseases, or may be drug-induced.
Adam Reich, Radomir Reszke
core +1 more source
Myelofibrosis is a myeloproliferative neoplasm that occurs de novo (primary myelofibrosis) or results from the progression of polycythemia vera or essential thrombocytemia (hereafter designated as secondary myelofibrosis or post-polycythemia vera ...
Mandy Brecqueville +12 more
doaj +1 more source

